NASDAQ
35.75USD
+0.75 (+2.14%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.8B
P/E
—
EPS
—
Beta
0.24
52W range
25.83-57.99
Day range
34.79–36.40
Open
35.00
Prev close
35.00
Volume
721.4K
Avg volume
1.2M
Dividend
0.00
IPO
2018-07-18
https://www.globenewswire.com/news-release/2026/06/14/3311468/0/en/Crinetics-Presents-Long-Term-Data-at-ENDO-2026-Confirming-PALSONIFY-paltusotine-Provides-Durable-Consistent-Acromegaly-Control.html · 6/14/2026+1.00
https://seekingalpha.com/article/4901143-crinetics-pharmaceuticals-inc-crnx-q1-2026-earnings-call-transcript · 5/8/2026+0.00
https://www.zacks.com/stock/news/2917505/crinetics-pharmaceuticals-inc-crnx-reports-q1-loss-beats-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2917505 · 5/7/2026-0.20
https://www.defenseworld.net/2026/04/12/charles-collier-sells-205821-shares-of-roku-nasdaqroku-stock.html · 4/12/2026-0.20
https://www.defenseworld.net/2026/04/12/jeff-knight-sells-85163-shares-of-crinetics-pharmaceuticals-nasdaqcrnx-stock.html · 4/12/2026
https://www.globenewswire.com/news-release/2026/03/26/3263394/0/en/Crinetics-Pharmaceuticals-Announces-Submission-of-Marketing-Authorization-Application-in-Brazil-for-Palsonify-Paltusotine-in-Acromegaly.html · 3/26/2026+0.80
https://www.defenseworld.net/2026/02/07/crinetics-pharmaceuticals-inc-nasdaqcrnx-given-consensus-rating-of-moderate-buy-by-analysts.html · 2/7/2026+0.80
https://www.globenewswire.com/news-release/2026/01/05/3213179/0/en/Crinetics-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Stock.html · 1/5/2026-0.20
https://www.globenewswire.com/news-release/2025/12/18/3208172/0/en/Crinetics-Pharmaceuticals-to-Participate-in-The-44th-Annual-J-P-Morgan-Healthcare-Conference.html · 12/18/2025+0.20
https://www.defenseworld.net/2025/12/06/capital-fund-management-s-a-makes-new-424000-investment-in-crinetics-pharmaceuticals-inc-crnx.html · 12/6/2025+0.20
https://www.fool.com/coverage/filings/2025/11/27/biotech-fund-dumps-usd12-3-million-in-crinetics-stock-as-shares-remain-19-lower-on-the-year/ · 11/27/2025-0.40
https://www.globenewswire.com/news-release/2025/11/20/3192379/0/en/Crinetics-Announces-First-Patient-Randomized-in-Pivotal-Phase-3-CAREFNDR-Trial-Evaluating-Paltusotine-in-Carcinoid-Syndrome.html · 11/20/2025+0.80
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
